On 30 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its interim report for the third quarter, 2013.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 14:00 CET. The event will be hosted by Sobi`s CEO and President, Geoffrey McDonough, and the presentation will be held in English.
The presentation can be followed live, or afterwards on our website, www.sobi.com. Slides used in the presentation will be made available on our website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 505 564 83
UK: +44 203 194 0544
US: +1 877 788 9023
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (SOBI.ST) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information - not for publication
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +46 8 697 20 00|
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE